expensive clinical studies and the barriers to market access. Unlike chemical-based prescription drugs, biologic drugs are derived from living cells. They are used to treat cancers, immunological diseases and other chronic illnesses. Biosimilars are generic versions of biological drugs that are similar to innovative biological drugs. The Patient Protection and Affordable Care Act (PPACA) became law in 2010. Section XII of the law allows an abbreviated approval pathway for biosimilars. FDA is currently
Words: 1491 - Pages: 6
Federal Trade Commission announced that Watson Pharmaceutical Inc. proposed a $1.7 billion acquisition against rival generic drug company Arrow Pharmaceutical owners by Robin Hood Holdings Limited. Watson alleged that the transaction would substantially reduce competition in the U.S. markets for important generic drug Cabergoline used to treat Parkinson's disease and generic drug Dronabinol used to treat side effects from chemotherapy. For the commission to be satisfied, the two companies
Words: 638 - Pages: 3
practices. One, called parallel importing, allowed importers in South Africa to purchase drugs from the cheapest source available, regardless of whether the patent holders had given their approval or not. Thus South Africa asserted its right to import “generic versions” of drugs that are still patent protected. The government did this because it claimed to be unable to afford the high cost of medicines that were patent protected. The other practice, called compulsory licensing, permitted the South African
Words: 1709 - Pages: 7
the word because this period is limited in time. It is perhaps better to describe it as a limited warranty. There are also other limitations. Pharmaceutical companies in some countries may not respect intellectual property and may copy or produce generic drugs even before the patent expires. An important criterion of a monopoly is price control. However, in many countries, a governmental agency is responsible for setting the prices of drugs, making the influence of the manufacturers somewhat limited
Words: 858 - Pages: 4
Stephan Danner, Aleksandar Ruzicic, Patrick Biecheler Study Commercial excellence in the pharmaceutical industry Delivering superior value to your customers in challenging times Stephan Danner, Aleksandar Ruzicic, Patrick Biecheler Study Commercial excellence in the pharmaceutical industry Delivering superior value to your customers in challenging times 2 | Study Contents Letter from the authors Executive summary 1. At a glance: Turbulent times, here to stay? 2. Taking
Words: 8654 - Pages: 35
MBA502 Economic Theory and Applications: Chapter 8 Applicable Questions (Pg: 220): 1) Find and label the monopolist’s profit-maximizing output and price: The chart shown below represents monopolistic competition, short run. P MC P1 MR D
Words: 605 - Pages: 3
players; 1000 smaller companies - focus: pipeline – new drugs in the process of development - 15% of sales into R&D - generics: 20-30% decrease in price after patent expiration - GENERIC DRUG COMPANIES: o majority of revenues from selling generic drugs + generic active pharmaceutical ingredients (APIs) o sell packed version of the drug under own name or o sell generic APIs to other pharmaceuticals – package and sell o strict regulatory approval o success: low-cost production capabilities
Words: 806 - Pages: 4
COUNTRY ANALYSIS REPORT: MEXICO VS U.S.A HEALTHCARE MERCK - DIABETES Group 14 – Campus Santa Fe: Angelica Hidalgo 1461526 Alejandro Meza 1464801 Cinthia Merlos 1462113 Juan José Ibarra 1465263 April 10th, 2012 INDEX 1. INTRODUCTION 2. ECONOMIC VARIABLES
Words: 4412 - Pages: 18
Claris Lifesciences Claris Lifescienceswas originally founded as Oracle Laboratories Limited on July 19, 1994, as a public limited company. They received the certificate for commencement of business on July 28, 1994. Subsequently, the company name was changed to Core Laboratories Limited as they were acting as the marketing and distribution agent for Core Healthcare Limited at the time. They changed the name of the Company again to Claris Lifesciences Limited on March 31, 1999. Since then, Claris
Words: 835 - Pages: 4
dollars in revenues on prescription drugs that have patent protection. Once a drug loses its patent protection, other manufacturers are allowed to make a generic form of the drug. Having a generic form of a brand name drug available should increase the supply in the market for consumers by driving cost down. This paper will discuss the effect of generic drugs and evaluate their effect on the supply and demand for drugs that no longer have patent protection. An example of a prescription drug that recently
Words: 1447 - Pages: 6
